What question did this study set out to answer?

The aim is to assess the incidence and clinical implications of late immune effector cell-associated hematologic toxicity after CD19 CAR-T therapy.

Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization

View Full Paper

Ask AI

Bookmark

Authors

Retrospective review reports late hematologic toxicity occurrence in adults, highlighting its clinical significance.

The aim is to assess the incidence and clinical implications of late immune effector cell-associated hematologic toxicity after CD19 CAR-T therapy.
Conducted a retrospective review of 156 adults receiving CD19 CAR-T therapy
Analyzed the incidence and duration of late immune effector cell-associated hematologic toxicity
Utilized cumulative incidence analysis with controls for disease progression and death
Evaluated resource utilization among a subset of patients
Late hematologic toxicity occurred in 39% of patients, with a median duration of 183 days
20% of patients experienced ICAHT lasting over 1 year
Overall survival rates were similar between those with and without late ICAHT
HEMATOTOX score significantly associated with the development of late ICAHT
Growth factors represented the primary cost driver for healthcare resources used

Giguère et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark